PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Oral Oncology Supplement10.1016/j.oos.2009.06.19620093193O111. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neckP. Specenier, M. Rasschaert, Ph. Vromanhttps://api.elsevier.com/content/article/PII:S1744789509001977?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1744789509001977?httpAccept=text/plain
Head & Neck10.1002/hed.10172200224121054-1059A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neckEnrique Espinosa, Pilar Zamora, Alfredo Millá, Serafin Morales, Raquel Molina, M. Mira, Manuel González Barónhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhed.10172, https://onlinelibrary.wiley.com/doi/full/10.1002/hed.10172
The Korean Journal of Internal Medicine10.3904/kjim.2017.23420193451107-1115Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neckMoon Jin Kim, Sung Min Kim, Hyun Ae Jung, Jung Yong Hong, Won Jin Chang, Moon Ki Choi, Hye Sook Kim, Jong-Mu Sun, Keunchil Park, Myung-Ju Ahnhttp://kjim.org/upload/kjim-2017-234.pdf, http://kjim.org/journal/view.php?doi=10.3904/kjim.2017.234, http://kjim.org/upload/kjim-2017-234.pdf
Head and Neck Cancer10.1007/978-3-319-27601-4_422016711-729Systemic Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckPetr Szturz, Jan B. Vermorkenhttp://link.springer.com/content/pdf/10.1007/978-3-319-27601-4_42
The Laryngoscope10.1097/01.mlg.0000208366.34683.5820061164613-618Phase II Study of Weekly Docetaxel and Cisplatin in Patients With Advanced Recurrent and Metastatic Head and Neck CancerOrlando Guntinas-Lichius, Stefan Appenrodt, Florian Veelken, Barbara Krughttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1097%2F01.mlg.0000208366.34683.58, https://onlinelibrary.wiley.com/doi/full/10.1097/01.mlg.0000208366.34683.58
Head & Neck10.1002/hed.236042015374471-478PI3K/PTEN/AKT/mTOR polymorphisms: Association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab-docetaxelKatharina Pfisterer, Alberto Fusi, Konrad Klinghammer, Maren Knödler, Anika Nonnenmacher, Ulrich Keilholzhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhed.23604
Auris Nasus Larynx10.1016/j.anl.2015.02.0092015425396-400Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinomaHironori Cho, Suetaka Nishiike, Yoshifumi Yamamoto, Yukinori Takenaka, Susumu Nakahara, Toshimichi Yasui, Atsushi Hanamoto, Hidenori Inoharahttps://api.elsevier.com/content/article/PII:S0385814615000334?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0385814615000334?httpAccept=text/plain
Head & Neck10.1002/hed.219102011353443-453Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neckDong M. Shin, Fadlo R. Khurihttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhed.21910
Cancer10.1002/cncr.2157920061061106-111Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neckRicardo Hitt, Maria L. Amador, Miguel Quintela-Fandino, Antonio Jimeno, Olga del Val, Susana Hernando, Hernan Cortes-Funeshttp://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.21579, https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.21579
Cancer Chemotherapy and Pharmacology10.1007/s00280-009-0999-4200965127-32Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neckByoung Chul Cho, Ki Chang Keum, Sang Joon Shin, Hye Jin Choi, Young Joo Lee, Se Hun Kim, Eun Chang Choi, Joo Hang Kimhttp://link.springer.com/content/pdf/10.1007/s00280-009-0999-4.pdf, http://link.springer.com/article/10.1007/s00280-009-0999-4/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00280-009-0999-4